Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | IL1RN | P18510 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870453 | 1.00 | TSHR (0.46) | TSHRKDM4EHPGDNR4A2MEN1 | |
| SCHEMBL7223746 | 0.84 | TSHR (0.43) | TSHRHPGDMEN1HTTKMT2A | |
| SCHEMBL8254263 | 0.84 | TSHR (0.43) | TSHRHPGDMEN1HTTKMT2A | |
| SCHEMBL23064152 | 0.82 | TSHR (0.49) | TSHRHPGDMEN1HTTKMT2A | |
| SCHEMBL23064151 | 0.82 | TSHR (0.49) | TSHRHPGDMEN1HTTKMT2A | |
| SCHEMBL5869630 | 0.81 | HPGD (0.46) | TSHRHPGDMEN1HTTKMT2A | |
| SCHEMBL8248665 | 0.81 | HPGD (0.46) | TSHRHPGDMEN1HTTKMT2A | |
| SCHEMBL28226603 | 0.80 | GRIK1 (0.55) | TSHRIL1RNERAP2ERAP1GRIK1 | |
| SCHEMBL10482476 | 0.79 | AOC3 (0.47) | TSHRHPGDMEN1HTTKMT2A | |
| SCHEMBL7378945 | 0.78 | MEN1 (0.48) | HPGDMEN1KMT2AAOC3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | TSHR 2420/4885KDM4E 2662/4885HPGD 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.